Compare FFIC & RGNX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | FFIC | RGNX |
|---|---|---|
| Founded | 1929 | 2008 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Major Banks | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 510.6M | 528.6M |
| IPO Year | 1996 | 2015 |
| Metric | FFIC | RGNX |
|---|---|---|
| Price | $15.47 | $6.65 |
| Analyst Decision | Hold | Strong Buy |
| Analyst Count | 1 | 8 |
| Target Price | $16.80 | ★ $28.75 |
| AVG Volume (30 Days) | 393.6K | ★ 2.0M |
| Earning Date | 04-28-2026 | 05-05-2026 |
| Dividend Yield | ★ 5.50% | N/A |
| EPS Growth | ★ 151.43 | 18.08 |
| EPS | ★ 0.17 | N/A |
| Revenue | $7,455,000.00 | ★ $10,393,000.00 |
| Revenue This Year | $14.57 | $51.21 |
| Revenue Next Year | $6.64 | $19.08 |
| P/E Ratio | $91.00 | ★ N/A |
| Revenue Growth | 7.31 | ★ 126.48 |
| 52 Week Low | $11.13 | $5.46 |
| 52 Week High | $17.79 | $16.19 |
| Indicator | FFIC | RGNX |
|---|---|---|
| Relative Strength Index (RSI) | 42.77 | 45.13 |
| Support Level | $14.47 | $5.46 |
| Resistance Level | $15.55 | $7.32 |
| Average True Range (ATR) | 0.31 | 0.43 |
| MACD | -0.01 | 0.06 |
| Stochastic Oscillator | 29.46 | 52.43 |
Flushing Financial Corp is a bank holding company. Through its subsidiary, the company is engaged in attracting retail deposits from the general public and investing those deposits together with funds generated from ongoing operations and borrowings, mainly in originations and purchases of multi-family residential properties loans, commercial business loans, commercial real estate mortgage loans and, to a lesser extent, one-to-four family loans (focusing on mixed-use properties, which are properties that contain both residential dwelling units and commercial units). It also operates an internet branch, under the brands of iGObanking.com and BankPurely. The company operates as a single unit, a community bank.
Regenxbio Inc is a clinical-stage biotechnology company focused on the development of gene therapy treatments. Its product candidates are designed to deliver genes to cells to address genetic defects or enable the production of therapeutic proteins. The company is developing a pipeline of investigational gene therapy treatments using its NAV Technology Platform based on adeno-associated virus (AAV) vectors. Its internal research and development programs are focused on therapies for retinal, neuromuscular, and neurodegenerative diseases.